Two Promotions at InVivo Target Market Development of Neuro-Spinal Scaffold

Cambridge, Mass.-based InVivo Therapeutics Holdings Corporation has promoted two members of its management team to further drive market development and awareness of spinal cord injury innovation.

Christopher McNulty has been named senior vice president, business development and investor relations. He will continue to lead all business development and corporate communications efforts, including investor relations and public relations. This role is a promotion from his previous role as vice president, business development and investor relations. Before joining InVivo in November 2013, McNulty served as senior director of business development at Repligen Corporation. Previously, he was director of corporate development at Seventh Sense Biosystems, and associate director of business development and alliance management at Genzyme Corporation. He has an MBA from Harvard Business School and B.S. and master’s in engineering degrees from Massachusetts Institute of Technology (MIT).

Alex Aimetti, Ph.D., has been promoted to the newly created position of senior director, medical education and scientific support. In this new role, Aimetti will be responsible for leading and managing all professional medical education programs for InVivo. He joined InVivo in April 2012, and has served in positions of increasing responsibility including research and development (R&D) manager, biomaterials, and most recently Associate R&D Director, Biomaterials. Before joining InVivo, Aimetti was a postdoctoral research fellow in the laboratory of Robert Langer, Sc.D. at MIT. Aimetti received his B.S. from Worcester Polytechnic Institute and holds a doctorate in chemical and biological engineering from the University of Colorado Boulder.

“I am very pleased to be announcing these two key promotions today,” said Mark Perrin, CEO and chairman of InVivo. “Chris has been an integral part of the senior management team since joining us and continues to lead both business development and corporate communication initiatives. Upon assuming his investor relations responsibilities, Chris has been a key member of the team responsible for our expanded interactions with the financial community, recent capital raises, and our listing on the Nasdaq.

“Working cross-functionally, Alex will advance scientific communications related to our pipeline by leading the design and management of medical education programs and a range of non-promotional communication programs to health care providers and payers in the spinal cord injury market,” Perrin continued. “We have achieved significant clinical progress with the neuro-spinal scaffold and we look forward to communicating our advances to the medical community and other key constituencies.”

InVivo’s biodegradable neuro-spinal scaffold is surgically implanted at the epicenter of the wound following an acute spinal cord injury and is designed to act as a physical substrate for nerve sprouting. It is currently an investigation device with Humanitarian Use Device designation and is currently being studied in an Investigational Device Exemption pilot study for the treatment of patients with complete traumatic acute spinal cord injury.